| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H36O2 |
| Molecular Weight | 308.4986 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@](O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C
InChI
InChIKey=XVULBTBTFGYVRC-HHUCQEJWSA-N
InChI=1S/C20H36O2/c1-7-18(4,21)13-9-16-19(5)12-8-11-17(2,3)15(19)10-14-20(16,6)22/h7,15-16,21-22H,1,8-14H2,2-6H3/t15-,16+,18-,19-,20+/m0/s1
Sclareol isolated from Salvia officinalis is widely used as a fragrance material. Sclareol is known to exert various biological activities. Sclareol possesses high lipophilicity, that precluded the evaluation of its anticancer effect in vivo. To overcome high toxicity and high lipophilicity of clareol, it was incorporated in liposomes. It demonstrated significant cytotoxic activity against human leukemic cell lines, but no cytotoxicity towards normal cells at concentration as high as 100 uM. Thus, sclareol possesses chemotherapeutic potential for the treatment of colorectal and other types of human cancer. Also was found, that sclareol-containing cream improved wrinkles in a clinical trial. It alleviates facial wrinkle formation via an antiphotoaging mechanism and may be an effective candidate ingredient. The anti-inflammatory mechanisms of sclareol might be related to a decrease of inflammatory cytokines and an increase of antioxidant enzyme activity.
Approval Year
PubMed
Sample Use Guides
immunodeficient SCID mice: liposome-encapsulated sclareol
Route of Administration:
Intraperitoneal
Sclareol triggers phospholipid scrambling of the erythrocyte cell membrane, an effect in part due to activation of p38 kinase and casein kinase 1α. A 48 hours exposure of human erythrocytes to Sclareol (≥ 50 µM) significantly increased the percentage of annexin-V-binding cells without significantly modifying the average forward scatter. Sclareol (100 µM) significantly increased Fluo3-fluorescence, but the effect of Sclareol on annexin-V-binding was not significantly blunted by removal of extracellular Ca2+. Instead, the effect of Sclareol on annexin-V-binding was significantly blunted in the presence of p38 kinase inhibitor skepinone (2 µM) and in the presence of casein kinase 1α inhibitor D4476 (10 µM).
SUBSTANCE RECORD
